Answers are grounded in this paper and cite their sources.
E ach year, up to 400 million dengue virus (DENV) infections and 40,000 deaths occur globally, costing US $9 billion (1-3). Accurate estimates of disease are needed to track health progress, evaluate prevention and control technologies, and define research priorities (4). However, substantial heterogeneity exists in estimates of disease severity and sequelae (5). Research suggests dengue symptoms may persist well beyond the acute febrile phase in some patients (6-8). Little is known about health-related quality of life (HRQOL) for dengue Despite acknowledgement of symptom persistence since 1997 (9), most studies focus on the febrile phase, probably substantially underestimating long-term effects of dengue We investigated HRQOL of dengue patients during their entire laboratory-confirmed dengue episode.
No takes yet. Share an insight, caveat, or question.
Schulte et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: